司库奇尤单抗作为首个生物制剂治疗中重度银屑病与其他生物制剂在德国的成本效果比较
该分析采用52周决策树模型,从德国医疗系统角度比较司库奇尤单抗作为首个生物制剂与阿达木单抗、英夫利西单抗、依那西普和乌司奴单抗治疗中重度银屑病的每应答者成本。司库奇尤单抗的每PASI 90应答者成本最低,16周为18026欧元,52周为42409欧元,持续应答者成本为22690欧元。结论认为司库奇尤单抗作为首个生物制剂具有成本效果。
要点
- 司库奇尤单抗16周每PASI 90应答者成本为18026欧元,低于乌司奴单抗的18080欧元。
- 52周每PASI 90应答者成本司库奇尤单抗为42409欧元,依那西普为70363欧元。
- 司库奇尤单抗每持续52周PASI 90应答者成本为22690欧元,低于其他生物制剂。
核心结论
- 在德国,司库奇尤单抗作为中重度银屑病的首个生物制剂治疗具有成本效果,与其他生物制剂相比每应答者成本最低。
研究设计与样本
- 采用52周决策树模型,从德国医疗系统角度进行成本效果分析。
- 临床疗效数据来自混合治疗比较,资源单位成本来自2016年国家来源,不良事件和停药率来自文献。
- 根据第16周PASI应答将队列分为应答者(PASI≥75)、部分应答者(PASI 50至74)和无应答者(PASI<50)。
主要发现
- 16周每PASI 90应答者成本:司库奇尤单抗18026欧元,乌司奴单抗18080欧元,阿达木单抗23499欧元,英夫利西单抗29599欧元,依那西普34037欧元。
- 52周每PASI 90应答者成本范围从司库奇尤单抗42409欧元至依那西普70363欧元。
- 司库奇尤单抗每持续52周PASI 90应答者成本为22690欧元,低于其他生物制剂治疗。
- 排除患者共付费用的敏感性分析显示类似结果。
关键数值与推荐
- 应答者定义为PASI≥75,部分应答者为PASI 50至74,无应答者为PASI<50。
- 持续应答定义为第16周应答维持至第52周。
- 应答者在第16周继续初始治疗,部分应答者和无应答者转换为标准治疗,包括甲氨蝶呤、环孢素、光疗和局部皮质类固醇。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin 17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials. OBJECTIVE: This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept and ustekinumab in Germany. METHODS: A 52-week decision-tree model was developed. Response to treatment was assessed based on the likelihood of achieving a predefined Psoriasis Area and Severity Index (PASI) response to separate the cohort into responders (PASI ≥75), partial responders (PASI 50 to 74) and non-responders (PASI <50). Responders at week 16 continued initial treatment, whereas partial responders and non-responders were switched to standard of care, which included methotrexate, cyclosporine, phototherapy and topical corticosteroids. Sustained response was defined as 16-week response maintained at week 52. A German healthcare system perspective was adopted. Clinical efficacy data were obtained from a mixed-treatment comparison; 2016 resource unit costs from national sources; and adverse events and discontinuation rates from the literature. We calculated cost per PASI 90 responder over week 16 and week 52, as well as cost per sustained responder between weeks 16 and 52. RESULTS: Secukinumab had the lowest cost per PASI 90 responder over 16 weeks (€18 026) compared with ustekinumab (€18 080), adalimumab (€23 499), infliximab (€29 599) and etanercept (€34 037). Over 52 weeks, costs per PASI 90 responder ranged from €42 409 (secukinumab) to €70 363 (etanercept). Likewise, secukinumab had the lowest cost per sustained 52-week PASI 90 responder (€22 690) compared with other biologic treatments. Sensitivity analyses, excluding patient copayments, showed similar results. CONCLUSIONS: First biologic treatment with secukinumab for moderate to severe psoriasis is cost-effective, with lowest cost per responder compared with other biologic treatments in Germany.
引用
- Augustin M, McBride D, Gilloteau I, et al. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018. PMID: 29729105. doi:10.1111/jdv.15047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。